Fewer inbound opportunities. Better pre-screened conversations.
TSCIP is designed to reduce upstream screening burden by bringing forward a limited set of clinical-stage oncology assets with a buyer-specific strategic thesis, while protecting private buyer review and decision requirements.
Two ways to engage.
Private platform review: evaluate curated assets without creating an owner-visible signal. Thesis-led field engagement: TSCIP may approach your S&E, External Innovation, BD or franchise team when a covered asset appears relevant to your portfolio or stated strategic needs.
TSCIP does the upstream work
Asset selection, strategic framing and owner preparation occur before a buyer is asked to spend substantive time on the opportunity.
What reaches the buyer.
Pre-vetted asset
A clinical-stage opportunity selected for credible strategic relevance rather than a paid listing.
Buyer-specific thesis
Why the asset may matter to your strategy, portfolio, development needs or therapeutic backbones.
Residual uncertainty
What current evidence establishes and which decision issue remains unresolved.
Private response
You can identify a requirement, defer, decline or request follow-up without creating an owner-side surveillance signal.
Qualified owner access
Direct interaction occurs when your team elects to engage.
Re-engagement discipline
TSCIP can return only when the evidence or proposition has materially changed.
Strategic Asset Reviews.
A small buyer-matched slate—not another conference.
TSCIP can periodically convene an invitation-only review around one buyer or strategic theme. A typical session may feature four to five pre-vetted assets presented sequentially by their owners after TSCIP has already screened the fit. Participation is driven by buyer relevance, not sponsorship or listing fees.
Buyer confidentiality is protected.
Searches, views, saves, passes, named comments and company-specific requirements remain confidential unless your team authorizes disclosure. Asset owners receive synthesized TSCIP outputs rather than buyer surveillance.
Establish a confidential review path.
TSCIP can discuss the public model and the type of opportunities your organization wants filtered upstream.